Abstract
Alzheimer disease (AD) is a neurodegenerative disease that affects cognition, behavior and function. The etiology of the disease is unknown, however, the Primary Risk Factors for AD are aging, and family history. Neurofibrillary tangles (NFT) and amyloid-bearing neuritic plaques in the limbic and cerebral cortices are the characteristic neuropathologic lesions in brains of patients with AD. The NFT is mainly composed of hyprephosphorylated tau, whereas the major component of the neuritic plaques is the amyloid beta (Aβ) protein. The clinical diagnosis of probable AD is based on history, physical examination, neuropsychological testing, laboratory studies and neuroimaging techniques. However, there is no specific laboratory marker to support the diagnosis of definite AD or monitoring the progression of the disease. Several biochemical markers related to neuropathology have been identified in cerebrospinal fluid (CSF). We describe the studies of CSF or blood levels of amyloid β protein in patients with AD and age-matched nondemented controls. Due to the heterogeneity and complex nature of the disease, it is highly unlikely that that a single marker specific for AD will be found.
Keywords: Alzheimer disease, amyloid beta protein, cerebrospinal fluid, plasma
Current Alzheimer Research
Title: Amyloid Beta Protein as a Marker or Risk Factor of Alzheimers Disease
Volume: 4 Issue: 4
Author(s): Pankaj D. Mehta
Affiliation:
Keywords: Alzheimer disease, amyloid beta protein, cerebrospinal fluid, plasma
Abstract: Alzheimer disease (AD) is a neurodegenerative disease that affects cognition, behavior and function. The etiology of the disease is unknown, however, the Primary Risk Factors for AD are aging, and family history. Neurofibrillary tangles (NFT) and amyloid-bearing neuritic plaques in the limbic and cerebral cortices are the characteristic neuropathologic lesions in brains of patients with AD. The NFT is mainly composed of hyprephosphorylated tau, whereas the major component of the neuritic plaques is the amyloid beta (Aβ) protein. The clinical diagnosis of probable AD is based on history, physical examination, neuropsychological testing, laboratory studies and neuroimaging techniques. However, there is no specific laboratory marker to support the diagnosis of definite AD or monitoring the progression of the disease. Several biochemical markers related to neuropathology have been identified in cerebrospinal fluid (CSF). We describe the studies of CSF or blood levels of amyloid β protein in patients with AD and age-matched nondemented controls. Due to the heterogeneity and complex nature of the disease, it is highly unlikely that that a single marker specific for AD will be found.
Export Options
About this article
Cite this article as:
Mehta D. Pankaj, Amyloid Beta Protein as a Marker or Risk Factor of Alzheimers Disease, Current Alzheimer Research 2007; 4 (4) . https://dx.doi.org/10.2174/156720507781788891
DOI https://dx.doi.org/10.2174/156720507781788891 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proinflammatory Cytokines and Chemokines in Neonatal Brain Damage
Current Pediatric Reviews Prospective Evaluation of the Dosing Regimen of Vancomycin in Children of Different Weight Categories
Current Drug Safety Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
Current Pharmaceutical Design Colorimetric and Electrochemical Study on the Interaction Between Gold Nanoparticles and Unmodified DNA
Current Nanoscience Aminobisphosphonates as New Weapons for γ δ T Cell-Based Immunotherapy of Cancer
Current Medicinal Chemistry The Journey of the Non-Vascular Relief for Migraine: From ‘Triptans’ To ‘Ditans’
Current Clinical Pharmacology Biology and Clinical Relevance of Mannose-Binding Lectin
Drug Design Reviews - Online (Discontinued) Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach
Current Drug Targets Laccase Regulators in Anti-fungal Drug Discovery: Dark Lessons from the AIDS-related Pathogen, Cryptococcus
Current Enzyme Inhibition History and Milestones of Mouse Models of Autoimmune Diseases
Current Pharmaceutical Design Transmission Electron Microscopy as Key Technique for the Characterization of Telocytes
Current Stem Cell Research & Therapy Entropy Model for Multiplex Drug-Target Interaction Endpoints of Drug Immunotoxicity
Current Topics in Medicinal Chemistry The Methylerythritol Phosphate Pathway and its Significance as a Novel Drug Target
Current Pharmaceutical Biotechnology Antisense Oligonucleotides as an Innovative Therapeutic Strategy in the Treatment of High-Grade Gliomas
Recent Patents on CNS Drug Discovery (Discontinued) Membrane Targeted Chemotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis
Current Pharmaceutical Design Rediscovering the Antibiotics of the Hive
Recent Patents on Anti-Infective Drug Discovery Infrequent Infections in COPD
Current Respiratory Medicine Reviews Mass Spectrometry, Proteomics, Data Mining Strategies and Their Applications in Infectious Disease Research.
Anti-Infective Agents in Medicinal Chemistry Nanotech Revolution for the Anti-Cancer Drug Delivery through Blood- Brain-Barrier
Current Cancer Drug Targets Targeted Oncolytic Herpes Simplex Viruses for Aggressive Cancers
Current Pharmaceutical Biotechnology